Literature DB >> 32193531

Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.

Chandna Vasandani1, Xilong Li2, Hilal Sekizkardes3, Beverley Adams-Huet2, Rebecca J Brown4, Abhimanyu Garg1.   

Abstract

CONTEXT: Familial partial lipodystrophy, Dunnigan variety (FPLD2) is a rare autosomal dominant disorder resulting from LMNA causal variants, which is characterized by loss of subcutaneous fat from the extremities and predisposition to metabolic complications. The diagnostic value of various anthropometric measurements for FPLD2 remains unknown.
OBJECTIVE: To determine specificity and sensitivity of anthropometric measurements for the diagnosis of FPLD2.
METHODS: We measured skinfold thickness and regional body fat by dual energy X-ray absorptiometry (DXA) in 50 adult females and 6 males with FPLD2 at UT Southwestern and compared their data with the sex- and age-matched controls from the National Health and Nutrition Examination Survey (NHANES) 1999-2010. We further compared data from 1652 unaffected females from the Dallas Heart Study and 23 females with FPLD2 from the National Institutes of Health with the NHANES data.
RESULTS: The DXA-derived lower limb fat (%) had the best specificity (0.995) and sensitivity (1.0) compared with the upper limb fat, truncal fat, the ratio of lower limb to truncal fat, and triceps skinfold thickness for adult females with FPLD2. The lower limb fat below 1st percentile of NHANES females had a false-positive rate of 0.0054 and a false negative rate of 0. The diagnostic value of anthropometric parameters could not be determined for males with FPLD2 due to small sample size.
CONCLUSIONS: The lower limb fat (%) is the best objective anthropometric measure for diagnosing FPLD2 in females. Women with below the 1st percentile lower limb fat should undergo genetic testing for FPLD2, especially if they have metabolic complications. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Dunnigan; Lamin A/C; dual energy X-ray absorptiometry; familial partial lipodystrophy; skinfold thickness

Mesh:

Substances:

Year:  2020        PMID: 32193531      PMCID: PMC7202860          DOI: 10.1210/clinem/dgaa137

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Dual-energy X-ray absorptiometry study of body composition in patients with lipodystrophy.

Authors:  Cynthia M Valerio; Amélio Godoy-Matos; Rodrigo O Moreira; Lucia Carraro; Erika P Guedes; Regina S Moises; Patricia B Mory; Luciana Lopes de Souza; Luis Augusto Russo; Ana Cláudia Melazzi
Journal:  Diabetes Care       Date:  2007-03-23       Impact factor: 19.112

Review 2.  Nuclear envelope-related lipodystrophies.

Authors:  A C Guénantin; N Briand; G Bidault; P Afonso; V Béréziat; C Vatier; O Lascols; M Caron-Debarle; J Capeau; C Vigouroux
Journal:  Semin Cell Dev Biol       Date:  2013-12-30       Impact factor: 7.727

3.  "Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers.

Authors:  Rasimcan Meral; Benjamin J Ryan; Noemi Malandrino; Abdelwahab Jalal; Adam H Neidert; Ranganath Muniyappa; Barış Akıncı; Jeffrey F Horowitz; Rebecca J Brown; Elif A Oral
Journal:  Diabetes Care       Date:  2018-10       Impact factor: 19.112

4.  Generalized equations for predicting body density of women.

Authors:  A S Jackson; M L Pollock; A Ward
Journal:  Med Sci Sports Exerc       Date:  1980       Impact factor: 5.411

5.  Influence of body fat content and distribution on variation in metabolic risk.

Authors:  Gloria Lena Vega; Beverley Adams-Huet; Ron Peshock; Duwayne Willett; Brijen Shah; Scott M Grundy
Journal:  J Clin Endocrinol Metab       Date:  2006-08-22       Impact factor: 5.958

6.  Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety).

Authors:  A Garg
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

7.  Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22.

Authors:  J M Peters; R Barnes; L Bennett; W M Gitomer; A M Bowcock; A Garg
Journal:  Nat Genet       Date:  1998-03       Impact factor: 38.330

8.  A new method for body fat evaluation, body adiposity index, is useful in women with familial partial lipodystrophy.

Authors:  Amélio F Godoy-Matos; Rodrigo O Moreira; Cynthia M Valerio; Patricia B Mory; Regina S Moises
Journal:  Obesity (Silver Spring)       Date:  2011-11-17       Impact factor: 5.002

9.  Body composition study by dual-energy x-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation.

Authors:  Cynthia M Valerio; Lenita Zajdenverg; José Egídio P de Oliveira; Patricia B Mory; Regina S Moyses; Amélio F Godoy-Matos
Journal:  Diabetol Metab Syndr       Date:  2012-08-31       Impact factor: 3.320

Review 10.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

View more
  1 in total

1.  Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

Authors:  H Mosbah; B Donadille; M C Vantyghem; C Vigouroux; C Vatier; S Janmaat; M Atlan; C Badens; P Barat; S Béliard; J Beltrand; R Ben Yaou; E Bismuth; F Boccara; B Cariou; M Chaouat; G Charriot; S Christin-Maitre; M De Kerdanet; B Delemer; E Disse; N Dubois; B Eymard; B Fève; O Lascols; P Mathurin; E Nobécourt; A Poujol-Robert; G Prevost; P Richard; J Sellam; I Tauveron; D Treboz; B Vergès; V Vermot-Desroches; K Wahbi; I Jéru
Journal:  Orphanet J Rare Dis       Date:  2022-04-19       Impact factor: 4.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.